

# Drug Coverage Decision for B.C. PharmaCare

## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

<b>Drug</b>	<b>Rivaroxaban</b>
Brand Name	Xarelto®
Dosage Form(s)	15 and 20 mg tablets
Manufacturer	Bayer Canada Inc.
<b>Submission Review</b>	<b>New Indication</b>
Use Reviewed	For the treatment of pulmonary embolism (PE)
Common Drug Review (CDR)	Yes. <a href="http://www.cadth.ca/media/cdr/complete/SR0327_complete_Xarelto%20PEm_Mar-28-14.pdf">http://www.cadth.ca/media/cdr/complete/SR0327_complete_Xarelto%20PEm_Mar-28-14.pdf</a>
Drug Benefit Council (DBC)	DBC met on May 5, 2014, and considered various inputs including: final review completed by the Common Drug Review (CDR) on March 26, 2014, which included clinical and pharmacoeconomic evidence review material and the recommendation from the Canadian Drug Expert Committee (CDEC). The DBC also considered Patient Input Questionnaire responses from 1 patient and 1 caregiver, Clinical Practice Reviews from 2 specialists, Manufacturer comments, as well as a Budget Impact Assessment.
<b>Drug Coverage Decision</b>	<b>Limited coverage benefit.</b> <a href="http://www.health.gov.bc.ca/pharmacare/sa/saindex.html#list">http://www.health.gov.bc.ca/pharmacare/sa/saindex.html#list</a>
Date	September 30, 2014
Reason(s)	<b>Drug coverage decision is generally consistent with the DBC recommendation.</b> <ul style="list-style-type: none"> <li>• Rivaroxaban was similar to enoxaparin plus vitamin K antagonist (VKA), with respect to efficacy based on the incidence of recurrent DVT, non-fatal PE, or fatal PE.</li> <li>• Rivaroxaban was similar to enoxaparin plus VKA with respect to safety based on clinically relevant bleeding events but had less major bleeding events.</li> <li>• Rivaroxaban was cost saving compared with enoxaparin plus VKA when treating patients for up to six months and more costly for longer treatment duration.</li> </ul>
Other Information	None

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) gives advice to the Ministry. The Council looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C. and the drugs cost
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the Council
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, please visit  
<http://www.health.gov.bc.ca/pharmacare/outgoing/drugrevproc2.pdf>.

To find out more about the Pharmaceutical Services Division and the PharmaCare program, visit  
[www.health.gov.bc.ca/pharmacare](http://www.health.gov.bc.ca/pharmacare).

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.